Skip to main content

BioAffinity Raises $4M

NEW YORK (360Dx) – BioAffinity Technologies on Wednesday announced it raised more than $4 million in Series A financing.

Company President and CEO Maria Zannes said in a statement that the financing will go toward the commercialization of its lung cancer diagnostic and further development of additional cancer tests and cancer therapeutics.

The San Antonio, Texas-based company is commercializing a noninvasive, early-stage lung cancer test called CyPath. BioAffinity said the CyPath platform will be built out for other cancers, including prostate and cervical cancer. Its drug development division called OncoSelect Therapeutics develops targeted therapies for cancer.

In March, the San Antonio City Council authorized the San Antonio Economic Development Corporation to invest in BioAffinity.